Long-term Immune Responses to Vaccination in HIV-Infected Patients: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Vaccine-induced antibodies may wane more quickly in persons living with human immunodeficiency virus (HIV) than in healthy individuals. We reviewed the literature on vaccines routinely recommended in HIV-infected patients to estimate how seroprotection decreases over time in those who initially responded to immunization. For each study retrieved from the literature, the decrease of seroprotection was modeled with a log binomial generalized linear model, and data were pooled in a meta-analysis to provide estimates of seroprotection 2 and 5 years after the last vaccine administration. Our analyses confirmed that the duration of seroprotection was shorter in HIV-infected patients and that with current guidelines, a substantial proportion of patients would have lost protective antibodies before a booster was proposed. We therefore discuss the implications for the monitoring of antibody levels and timing of revaccination in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duration of Humoral Immunity to Common Viral and Vaccine Antigens
Amanna, I. J., Carlson, N. E., & Slifka, M. K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066092 · Cited by 1,286 · cited 1×
“sons, certain vaccine antigens, such as rubella, tetanus, and hepatitis A, induce more sustained responses than others [58].”
BackgroundEstimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
Siber, G. R., Chang, I., Baker, S., Fernsten, P., O’Brien, K. L., Santosham, M., Klugman, K. P., Madhi, S. A., Paradiso, P., & Kohberger, R. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.119 · Cited by 366 · cited 1×
“pneumococcal disease are not clearly defined, even in healthy persons [3].”
BackgroundComplex Correlates of Protection After Vaccination
Plotkin, S. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit048 · Cited by 240 · cited 1×
“of protection” [62].”
Rey, D., Krantz, V., Partisani, M., Schmitt, M.-P., Meyer, P., Libbrecht, E., Wendling, M.-J., Vetter, D., Nicolle, M., Kempf-Durepaire, G., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00389-8 · Cited by 219
Launay, O. (2011) · JAMA · doi:10.1001/jama.2011.351 · Cited by 181 · cited 1×
“compromised hosts [60], there was no clear trend in our meta-analysis indicating that this strategy would extend the duration of seroprotection among primary responders.”
BackgroundSelf-citationPensieroso, S., Cagigi, A., Palma, P., Nilsson, A., Capponi, C., Freda, E., Bernardi, S., Thorstensson, R., Chiodi, F., & Rossi, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901702106 · Cited by 165
Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV‐Infected Patients
Veit, O., Niedrig, M., Chapuis‐Taillard, C., Cavassini, M. L., Mossdorf, E., Schmid, P., Bae, H., Litzba, N., Staub, T., Hatz, C., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/597006 · Cited by 149 · cited 1×
“portion of patients with nonreactive titers increased from 17% to 23% during the 10-year period after vaccination [57].”
BackgroundLevin, M. J., Gershon, A. A., Weinberg, A., Song, L., Fentin, T., & Nowak, B. F. (2006) · The Journal of Infectious Diseases · doi:10.1086/505149 · Cited by 138
Madhi, S. A., Adrian, P. V., Kuwanda, L., Jassat, W., Jones, S., Little, T., Soininen, A., Cutland, C., & Klugman, K. P. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.09.019 · Cited by 136
Do children infected with HIV receiving HAART need to be revaccinated?
Sutcliffe, C. G., & Moss, W. J. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70116-x · Cited by 111 · cited 1×
“More generally, patients immunized while on HAART show prolonged seroprotection for most vaccine antigens, as illustrated in a recent review [59].”
BackgroundBekker, V., Scherpbier, H. J., Pajkrt, D., Jurriaans, S., Zaaijer, H. L., & Kuijpers, T. W. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2616 · Cited by 103 · cited 15×
“In sub-Saharan African children vertically infected with HIV, not receiving highly HIV/AIDS • CID 2014:58 (15 April) • 1131 D ow nloaded from https://academ ic.oup.com /cid/article/58/8/1130/355516 by guest on 27 M arch 2022 active antiretroviral therapy (HAART), and vaccinated in the first months of life, percentages…”
BackgroundMethodInfluentialCruciani, M., Mengoli, C., Serpelloni, G., Lanza, A., Gomma, M., Nardi, S., Rimondo, C., Bricolo, F., Consolaro, S., Trevisan, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.10.040 · Cited by 101 · cited 5×
“Red symbols represent 3 intramuscular 40-μg doses (Cooper et al [10] and Cruciani et al [8]).”
BackgroundInfluentialCooper, C. L., Angel, J. B., Seguin, I., Davis, H. L., & Cameron, D. W. (2008) · Clinical Infectious Diseases · doi:10.1086/533467 · Cited by 97 · cited 3×
“33%–61% at year 2 [8, 10], and 40% at year 5 [10].”
BackgroundAbzug, M. J., Pelton, S. I., Song, L., Fenton, T., Levin, M. J., Nachman, S., Borkowsky, W., Rosenblatt, H. M., MARCINAK, J. F., Dieudonne, A., et al. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000237830.33228.c3 · Cited by 97 · cited 3×
“5 μg/mL [40], or 1 μg/mL [40, 41, 48, 49, 52]; or”
MethodInfluentialWeinberg, A., Gona, P. N., Nachman, S., Defechereux, P. A., Yogev, R., Hughes, W., Wara, D. W., Spector, S. A., Read, J. S., Elgie, C., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/498979 · Cited by 88 · cited 2×
“For hepatitis A, yellow symbols represent 1 dose (Weinberg et al [24], Crum-Cianflone et al [21], Kernéis et al [22], and Launay et al [23]); red symbols, 2 doses (Kernéis et al [22] and Launay et al [23]).”
BackgroundMelvin, A. J., & Mohan, K. M. (2003) · PEDIATRICS · doi:10.1542/peds.111.6.e641 · Cited by 88 · cited 16×
“were vaccinated or revaccinated after the start of HAART (73% after 1 year [30], 40%–82% after 4 years [32]).”
BackgroundMethodResultInfluentialMoss, W. J., Scott, S., Mugala, N., Ndhlovu, Z. M., Beeler, J. A., Audet, S. A., Ngala, M., Mwangala, S., Nkonga‐Mwangilwa, C., Ryon, J. J., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/519169 · Cited by 85 · cited 3×
“For measles, yellow symbols represent 1 dose (Moss et al [31]); red symbols, 2 doses (Melvin and Mohan [30], Bekker et al [26], Brunell et al [27], and Fowlkes et al [29]).”
BackgroundMethodLaunay, O., Grabar, S., Gordien, E., Desaint, C., Jegou, D., Abad, S., Girard, P., Bélarbi, L., Guérin, C., Dimet, J., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318183a9c0 · Cited by 71 · cited 2×
“Percentages of seroprotection were not greater with three-dose schedules [22,23], as compared to standard two-dose schedule [21–24].”
BackgroundResultSelf-citationLong-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected Adults
Crum‐Cianflone, N. F., Wilkins, K. J., Lee, A. W.-T., Grosso, A. D., Landrum, M. L., Weintrob, A., Ganesan, A., Maguire, J. D., Klopfer, S. O., Brandt, C., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir180 · Cited by 68 · cited 3×
“For hepatitis A, yellow symbols represent 1 dose (Weinberg et al [24], Crum-Cianflone et al [21], Kernéis et al [22], and Launay et al [23]); red symbols, 2 doses (Kernéis et al [22] and Launay et al [23]).”
Backgroundal-Attar, I., Reisman, J., Muehlmann, M., & McIntosh, K. (1995) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199502000-00013 · Cited by 62 · cited 2×
“In HIV vertically-infected Sub-saharian African children not on HAART and vaccinated in the first months of life, percentages of seroprotection rapidly dropped during follow-up: 62%-73% of primary responders were still protected after 15 months [29,31], 41%-49% after 28 months [25,31],and 30% after 50 months [28].”
BackgroundGlaser, J. B., Volpe, S., Aguirre, A., Simpkins, H., & Schiffman, G. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.4.761 · Cited by 62 · cited 1×
“After PPSV23 vaccination in adults, rates of decrease in antibody concentrations were either similar [45, 48, 52, 53] or more rapid [46, 50] compared with those observed in healthy individ-”
ResultAbzug, M. J., Warshaw, M. G., Rosenblatt, H. M., Levin, M. J., Nachman, S., Pelton, S. I., Borkowsky, W., & Fenton, T. (2009) · The Journal of Infectious Diseases · doi:10.1086/605448 · Cited by 59
Madhi, S. A., Klugman, K. P., Kuwanda, L., Cutland, C., Käyhty, H. M., & Adrian, P. V. (2009) · The Journal of Infectious Diseases · doi:10.1086/597388 · Cited by 56
Al-Attar, I., Reisman, J. J., Muehlmann, M., et al. (1995) · PubMed · Cited by 52
Farquhar, C., Wamalwa, D. C., Selig, S., John-Stewart, G. C., Mabuka, J. M., Majiwa, M., Sutton, W. F., Haigwood, N. L., Wariua, G., & Lohman-Payne, B. L. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181903ed3 · Cited by 50 · cited 13×
“In sub-Saharan African children vertically infected with HIV, not receiving highly HIV/AIDS • CID 2014:58 (15 April) • 1131 D ow nloaded from https://academ ic.oup.com /cid/article/58/8/1130/355516 by guest on 27 M arch 2022 active antiretroviral therapy (HAART), and vaccinated in the first months of life, percentages…”
BackgroundInfluentialWismans, P. J., van Hattum, J., GAST, G. C. D., Bouter, K. P., Diepersloot, R. J. A., Maikoe, T., & Mudde, G. C. (1991) · Journal of Medical Virology · doi:10.1002/jmv.1890350313 · Cited by 49 · cited 1×
“even in individuals with low antibody concentrations [61].”
BackgroundTejiokem, M. C., Gouandjika, I., Béniguel, L., Endegue-Zanga, M. C., Tene, G., Gody, J. C., Njamkepo, E., Kfutwah, A. K. W., Penda, C. I., Bilong, C., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001260 · Cited by 49
Pacanowski, J., Lacombe, K., Campa, P., Dąbrowska, M. M., Poveda, J., Meynard, J., Poirot, J.-L., Fonquernie, L., & Girard, P. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318249de59 · Cited by 46 · cited 1×
“[21, 22], yellow fever [55] and Pneumococcus vaccines [43].”
BackgroundHepatitis B vaccination in HIV-1-infected children: double efficacy doubling the paediatric dose.
Scolfaro, C., Fiammengo, P., Balbo, L., Madon, E., & Tovo, P. (1996) · PubMed · Cited by 44
Abzug, M. J., Song, L., Fenton, T., Nachman, S., Levin, M. J., Rosenblatt, H. M., Pelton, S. I., Borkowsky, W., Edwards, K. M., & Peters, J. (2007) · PEDIATRICS · doi:10.1542/peds.2007-0729 · Cited by 41 · cited 2×
“the only study available for the vaccine (n = 4; pertussis [4],H.”
BackgroundGibb, D. M., GIACOMELLI, A., MASTERS, J., Spoulou, V. I., Ruga, E. M., Griffiths, H. R., Kroll, S., Giaquinto, C., & Goldblatt, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199612000-00008 · Cited by 39 · cited 2×
“influenzae b, estimates of seroprotection ranged from 16% to 78% [5, 30, 54] in children with”
BackgroundFowlkes, A. L., Witte, D., Beeler, J. A., Audet, S. A., Garcia, P., Curns, A. T., Yang, C., Fudzulani, R., Broadhead, R., Bellini, W. J., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir135 · Cited by 35 · cited 3×
“In HIV vertically-infected Sub-saharian African children not on HAART and vaccinated in the first months of life, percentages of seroprotection rapidly dropped during follow-up: 62%-73% of primary responders were still protected after 15 months [29,31], 41%-49% after 28 months [25,31],and 30% after 50 months [28].”
BackgroundResultBarbi, M., Biffi, M. R., Binda, S., Clerici-Schoeller, M., Ferraris, G., Luraschi, C., Masellat, P., Mazzoni, P., Pozzi, A., Pregliasco, F. E., et al. (1992) · AIDS · doi:10.1097/00002030-199212000-00007 · Cited by 34 · cited 1×
“One study each reported data on immunization against poliovirus [37], pertussis [4], and diphtheria [34].”
BackgroundRigaud, M., Borkowsky, W., Muresan, P., Weinberg, A., LaRussa, P. S., Fenton, T., Read, J. S., Jean‐Philippe, P., Fergusson, E., Zimmer, B., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/592050 · Cited by 33 · cited 2×
“53 months after immunization (Figure 2E) [28, 30, 32–34, 37– 39].”
BackgroundLao‐Araya, M., Puthanakit, T., Aurpibul, L., Taecharoenkul, S., Sirisanthana, T., & Sirisanthana, V. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.03.077 · Cited by 24 · cited 2×
“For hepatitis B, yellow symbols represent 3 intramuscular 10-μg doses (Lao–Araya et al [13] and Scolfaro et al [18]) or 3 subcutaneous 5-μg doses (Mannucci et al [14]) in children or 3 intramuscular 20-μg doses in adults (Kaech et al [12] and Rey et al [17]).”
BackgroundFernandes, S. J., Slhessarenko, N., & Souto, F. J. D. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.020 · Cited by 18
Cited by
Frater, J., Ewer, K. J., Ogbe, A., Pace, M., Adele, S., Adland, E., Alagaratnam, J., Aley, P. K., Ali, M., Ansari, M. A., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00103-x · Cited by 229
“31 However, in view of concerns regarding the potential for worse outcomes with COVID-19 for people with HIV combined with anxiety over less effective immune responses to vaccination, these preliminary data showing good early immunity are reassuring.”
Background
Metadata
- Authors
- Kerneis, S., Launay, O., Turbelin, C., Batteux, F., Hanslik, T., & Boelle, P.-Y.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-10
- Volume
- 58
- Issue
- 8
- Pages
- 1130-1139
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2120079411
- Cited by
- 190
- References
- 36
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.